MedTrace Logo

Pharmacodynamic Properties of CJ-12420 on Evening Dosing

NCT03043521 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-02-06

No results posted yet for this study

Summary

The purpose of this study is to compare and evaluate impact on pharmacodynamic characteristics of CJ-12420 and dexlansoprazole with evening dosing in healthy male volunteers

Conditions

  • Healthy

Interventions

DRUG

Dexlansoprazole 60 MG

DRUG

CJ-12420 50mg

DRUG

CJ-12420 100mg

DRUG

CJ-12420 200mg

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • Eunji Kim · CJ HealthCare Corp.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-13
Primary Completion
2015-08-12
Completion
2015-08-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03043521 on ClinicalTrials.gov